Funding · 10 August 2026Biodeal Pharmaceuticals₹385 croreContract development and manufacturing organisationbiodealpharma.com ↗
FundingHealthcare & Life Sciences
Biodeal raises ₹385 crore from RMB Capitalworks
By Abha Lohia · Editor ·
Biodeal Pharmaceuticals: revenue and funding and every story →
growthNoidaFounded 2005
- Biodeal Pharmaceuticals is a CDMO that manufactures drugs and formulations for global pharma brands
- It raised ₹385 crore from RMB Capitalworks, its first equity raise in two decades
- The funds will be used for business expansion and R&D for new molecules, targeting ₹500 crore revenue in FY27
What happened
- Biodeal Pharmaceuticals announced a ₹385 crore investment from RMB Capitalworks, a unit of South African lender FirstRand Bank.
- This is the first equity raise by Biodeal in its two-decade history.
- The stake acquired by RMB Capitalworks is undisclosed.
- RMB Capitalworks Managing Partner is Anshuman Malur.
- The funds will be used for business expansion and R&D for new molecules.
- Biodeal plans to expand into new segments.
- The company reported FY26 revenue of ₹325 crore with an operating profit margin of 20%.
- It targets FY27 revenue of ₹500 crore and FY30 revenue of ₹1,200 crore.
Why it matters
- Biodeal has been bootstrapped for 20 years and is now raising external capital for the first time.
- The investment comes from a South African financial group, indicating cross-border interest in Indian pharma CDMOs.
- The company's revenue target of ₹1,200 crore by FY30 suggests a 3.7x growth plan over four years.
The business
- Biodeal Pharmaceuticals is a contract development and manufacturing organisation (CDMO).
- It serves 500+ pharma companies across 80+ countries.
- The company has developed 1,000+ formulations and holds 30+ accreditations including WHO-GMP, PIC/S, ISO, Health Canada, and AYUSH.
- It operates 10 manufacturing blocks across two factories in Himachal Pradesh.
- Production capacity includes 3 billion tablets/year, 650 million capsules/year, and 30 million nasal spray units/year.
- Biodeal is a pioneer in nasal spray and DPI manufacturing in India and manufactures Allegra Nasal for Sanofi.
- It has four verticals: Pharmaceuticals, Derma & Cosmetics, Nutraceuticals, and Herbaceuticals.
- The company has 1,200+ employees and 35 R&D scientists in DSIR-approved labs.
- It offers four engagement models: Contract Manufacturing, Loan Licensing, R&D, and Nasal & DPI Systems.
The founders
- Anurag Kumar is the Chairman and Managing Director of Biodeal Pharmaceuticals.
- He has led the company since its founding in 2005.
Who put in money
- RMB Capitalworks lead — RMB Capitalworks is a unit of South African lender FirstRand Bank, led by Managing Partner Anshuman Malur.
In numbers
₹325 croreFY26 revenue
20%FY26 operating profit margin
₹500 croreFY27 revenue target
₹1,200 croreFY30 revenue target
500+Pharma companies served
80+Countries served
1,000+Formulations developed
30+Accreditations
10Manufacturing blocks
1,200+Employees
3 billion/yearTablet production capacity
650 million/yearCapsule production capacity
30 million units/yearNasal spray production capacity
35R&D scientists
What happens next
- Biodeal will use the funds for business expansion and R&D for new molecules.
- The company plans to expand into new segments.
- It targets ₹500 crore revenue in FY27 and ₹1,200 crore by FY30.
Up against
Laurus LabsDivis LaboratoriesPiramal Pharma SolutionsSyngene International
Words to know
- CDMO
- Contract Development and Manufacturing Organisation – a company that provides drug development and manufacturing services to other pharmaceutical companies on a contract basis.
- DPI
- Dry Powder Inhaler – a device that delivers medication in powder form to the lungs, used for respiratory conditions like asthma.
- WHO-GMP
- World Health Organization Good Manufacturing Practices – international quality standards for pharmaceutical production.
- PIC/S
- Pharmaceutical Inspection Co-operation Scheme – a set of quality standards for pharmaceutical manufacturing used by regulatory authorities worldwide.
The numbers around it
Healthcare & Life Sciences in August 2026: 10 rounds with a disclosed amount, $139 million in all; the biggest was Biodeal Pharmaceuticals (₹385 crore). Every sector this year →
Terms in this story
- Financial year: An Indian financial year runs from 1 April to 31 March, and it is named after the year it ends. FY26 means April 2025 to March 2026. Startup results for a year arrive months after it closes, so a November 2026 story may still be about FY25.
Read next
FundingAugust AI raises $12M for US expansionAugust AI offers an AI health assistant that answers medical questions through WhatsApp and a mobile appFundingVitusCare raises $3 million Series BVitusCare runs dialysis units inside partner hospitals, which keeps costs low, and has grown from 22 to over 60 centresLaunchKapiva gives away Dia Free Juice on World Diabetes DayKapiva is a Bengaluru-based Ayurveda wellness brand selling herbal juices and supplements, with a flagship juice aimed at people managing blood sugar
Everything on Biodeal Pharmaceuticals → · All startup news on 10 August 2026 →
Is this Biodeal Pharmaceuticals? Get your “Featured on StopDown” badge →